@prefix n9j: <http://data.loterre.fr/ark:/67375/N9J> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix isothes: <http://purl.org/iso25964/skos-thes#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .

n9j:-BZ3VRH22-V
  skos:prefLabel "new research frontiers on obesity"@en ;
  a skos:Concept ;
  skos:narrower n9j:-ZNPTKSJ5-F .

n9j:-concepts
  a isothes:ConceptGroup ;
  skos:prefLabel "concepts"@en ;
  skos:member n9j:-ZNPTKSJ5-F .

n9j:-ZNPTKSJ5-F
  owl:sameAs <https://concepts.sagepub.com/social-science/concept/acomplia> ;
  skos:definition "Acomplia is the trade name of rimonabant (generic name), which has been approved in the European Union (EU), Argentina, and Mexico for the treatment of obesity. As of March 2007, rimonabant (the proposed U.S. trade name is Zimulti) is under review by the Food and Drug Administration (FDA) and it is not yet available in the United States. [Source: Encyclopedia of Obesity; Acomplia]"@en ;
  a skos:Concept ;
  skos:inScheme n9j: ;
  skos:broader n9j:-BZ3VRH22-V ;
  skos:prefLabel "acomplia"@en .

n9j: a skos:ConceptScheme .